Abstract
Objectives
Acute severe ulcerative colitis (ASUC) poses challenges to patient management owing to its high surgical rate. This study aimed to identify predictors of colectomy in patients with ASUC.
Design
This is a systematic review and meta-analysis.
Data sources
PubMed and Web of Science were searched up to April 2024.
Eligibility criteria
Studies on the predictors of colectomy in adult patients with ASUC were eligible.
Data extraction and synthesis
Two reviewers independently extracted the data using a prespecified data collection sheet. A qualitative synthesis was performed in tabular form. Random-effect meta-analyses were conducted using OR and 95% CI.
Results
Forty-two studies were included in the systematic review. The reported variables can be categorised into biomarkers, auxiliary examination findings, demographic and clinical characteristics, and drug factors. Through meta-analysis, albumin (OR 0.39 (95% CI 0.26 to 0.59) per 1 g/dL increment, I2=0.0%), high C reactive protein level (2.63 (1.53 to 4.52), I2=29.6%), high erythrocyte sedimentation rate level (2.92 (1.39 to 6.14), I2=0.0%), low haemoglobin level (2.08 (1.07 to 4.07), I2=56.4%), fulfilling the Oxford criteria (4.42 (2.85 to 6.84), I2=0.0%), extensive colitis (1.85 (1.24 to 2.78), I2=47.5%), previous steroids (1.75 (1.23 to 2.50), I2=17.7%) or azathioprine (2.25 (1.28 to 3.96), I2=0.0%) use, and sarcopenia (1.90 (1.04 to 3.45), I2=0.0%) were identified as valuable predictors for colectomy within 1 year. The ulcerative colitis endoscopic index of severity (OR 2.41 (95% CI 1.72 to 3.39), I2=1.5%) was the only predictor found to predict colectomy over 1 year.
Conclusion
Identification of these predictors may facilitate risk stratification of patients with ASUC, drive personalised treatment and reduce the need for colectomy.
Keywords: ULCERATIVE COLITIS, IBD SURGERY, META-ANALYSIS
WHAT IS ALREADY KNOWN ON THIS TOPIC
Acute severe ulcerative colitis (ASUC) presents challenges in patient management with its high incidence and surgical rate.
Despite various predictors of colectomy, there is a lack of systematic review of their predictive efficacy, which is important for improving clinical decision-making.
WHAT THIS STUDY ADDS
Meta-analysis revealed that albumin levels, elevated C reactive protein, increased erythrocyte sedimentation rate, decreased haemoglobin, fulfilment of the Oxford criteria, extensive colitis, prior use of steroids or azathioprine, and sarcopenia are significant predictors of colectomy within 1 year.
The ulcerative colitis endoscopic index of severity emerged as the sole predictor for colectomy beyond 1 year.
HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
Identification of significant predictors for colectomy may facilitate risk stratification of patients with ASUC and drive personalised treatment, thereby reducing the need for colectomy.
Introduction
Acute severe ulcerative colitis (ASUC), characterised by bloody stools and systemic symptoms such as fever, tachycardia and anaemia, is a potentially life-threatening condition of ulcerative colitis (UC).1 Approximately 25% of patients with UC will experience such severe attacks at least once during their lifetime,2 3 with a projected mortality of approximately 1% and colectomy rates of approximately 30% during the first hospitalisation.2 4
Intravenous corticosteroids have been considered the cornerstone of therapy for hospitalised individuals with ASUC,1 while medical rescue therapy, including infliximab (IFX) and ciclosporin, is regarded as the first line that can be implemented to avoid emergency colectomy as much as possible for patients with steroid-refractory ASUC.1 5 However, colectomy as a definitive treatment for ASUC should be considered seriously from the beginning of admission. The increased risk of postoperative complications and mortality is associated with delayed or emergency surgery.6 Therefore, early identification of patients at high risk for colectomy is beneficial for clinicians to adopt targeted and more active medical treatment to prevent disease progression. Additionally, in the case of unavoidable surgery, it enables proactive decision-making regarding the right timing and method of surgery, with adequate preoperative preparation, rather than performing emergency surgery.
Previous studies have proposed several variables that can predict the outcomes of colectomy in patients with ASUC, including clinical symptoms, biomarkers, endoscopic or imaging parameters, and drug factors. Among these, C reactive protein (CRP), albumin, erythrocyte sedimentation rate (ESR) and faecal calprotectin are the most frequently studied variables with prognostic potential.6 7 However, the predictive power of some risk factors for colectomy has been mixed across studies, and the lack of systematic studies to address these controversies has hindered the use of these prognostic factors in clinical practice.7
Therefore, this study aimed to systematically review the predictors of colectomy in patients with ASUC identified in the existing literature and to further estimate the associations between these predictors and colectomy risk by meta-analysis.
Methods
Registration and reporting
This systematic review and meta-analysis is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses 2020 statement (online supplemental table S1).8 The study protocol was registered in the International Prospective Register of Systematic Reviews (registration number CRD42022361905).
Search strategy
We systematically searched PubMed and Web of Science, and the final search was conducted in April 2024. Additionally, the reference lists of the enrolled studies and related reviews were manually searched as supplements. The search terms included UC, colectomy, prediction, prognosis and their corresponding synonyms. The search was restricted to articles published in English. Document types other than original articles, such as review papers, conference abstracts, letters and editorial materials, were filtered. Online supplemental table S2 provides comprehensive details of the search strategies used.
Study selection
Literature pertaining to the predictors of colectomy in adult patients with ASUC was deemed eligible, including both cohort and case-control studies with full texts. A diagnosis of ASUC was made based on the Truelove and Witts criteria, which were defined as six or more bloody stools per day and at least one manifestation of systemic inflammation, including fever, tachycardia, anaemia or increased inflammatory markers,9 or physician assessment in cases where patients with UC exhibited severe clinical symptoms. We did not impose any restrictions on the baseline settings of the included studies, and any pharmaceutical intervention subsequent to baseline was allowed. The primary outcome of our study was the occurrence of colectomy within a 1-year timeframe after baseline, and the secondary outcomes included colectomy that occurred within 90 days and during follow-up of more than 1 year.
To determine whether the retrieved articles met the pre-established eligibility criteria, two reviewers (ZF and RC) independently screened the titles and abstracts and then conducted comprehensive reviews of the full texts of the selected articles. Discrepancies were resolved through consultation to reach a consensus.
Data extraction
Two reviewers (ZF and JZ) independently extracted the data from the enrolled studies using a prespecified data collection sheet. The data recorded included the principal author, publication year, study design and data source, country of the study, sample size, participant characteristics, definition of ASUC, outcomes and follow-up period, risk factors studied, concomitant medications and measures of effect such as OR and its corresponding 95% CI. Discrepancies in extracted information were resolved by a third reviewer (RC) through adjudication.
Study quality assessment
The Newcastle-Ottawa Scale was used to evaluate the quality of the studies, which comprised three dimensions as follows: selection of the population (four items), comparability of the study groups (one item) and the outcome assessment (three items). Each item was assigned a maximum score of 1, except for comparability, which was assigned a maximum score of 2. Studies with total scores ranging from 4 to 6 and 7 to 9 were considered of moderate and high quality, respectively, and were included in subsequent analyses. The assessments were independently completed by two reviewers (ZF and DW). Disagreements were resolved through discussion.
Data synthesis and statistical analysis
To evaluate the overall predictive effects of the candidate predictors proposed in the included studies on colectomy in patients with ASUC, data synthesis was conducted separately for different predictors and outcomes. We categorised outcomes into colectomies occurring within 1 year, within 90 days and after more than 1 year while disregarding the potential variances within these respective periods. For predictors with available ORs and corresponding 95% CIs in two or more studies, we performed a random-effect meta-analysis to calculate the overall ORs and 95% CIs. The ORs for continuous and categorical variables were pooled separately, whereas categorical variables with slightly different cut-off values were considered the same variable. Cochran’s Q test and the I2 statistic were used to assess the presence and extent of statistical heterogeneity among the studies, respectively. An I2 statistic >50% or p≤0.10 indicated substantial heterogeneity.10 For risk factors mentioned in only one study or lacking sufficient data for OR calculations, the area under the receiver operating characteristic curve, sensitivity, specificity or the mean/median differences of the risk factors between two patient groups (those undergoing colectomy vs those not) were summarised via tabulation and descriptive analysis.
Given that Truelove and Witt’s criteria have long been the gold standard for diagnosing ASUC, we performed a sensitivity analysis of predictors from studies employing Truelove and Witt’s criteria for diagnosis to test the robustness and reliability of the results of the primary outcome.
All analyses were conducted using Stata MP V.16.0.
Results
Study selection and characteristics
We retrieved 10 753 records from the databases (5944 from PubMed and 4809 from the Web of Science), with 8175 records remaining after the removal of duplicates. Through title and abstract screening, 80 articles were deemed eligible and subjected to full-text evaluation. Ultimately, 42 articles were included in this review, of which 35 had sufficient data to be included in the meta-analysis11,45 (online supplemental figure S1).
As shown in table 1, four of the eligible studies had prospective designs,24 28 30 46 and the rest were retrospective analyses. Colectomy occurred within 1 year in 27 studies,11,2334 and during a follow-up period of more than 1 year in 10 studies.2527,32 38 50 51 Five studies24 26 33 43 52 reported both 1-year and long-term outcomes. Sample sizes ranged from 18 to 489 patients. Thirty studies used the Truelove and Witts criteria to define ASUC,11,1517 20 whereas 12 studies diagnosed ASUC based on severe acute clinical attacks.13 15 16 18 19 23 25 28 33 34 38 40 42 50 The detailed study characteristics are provided in online supplemental table S3. Given the random effect analysis, the pooled rates of colectomy within 90 days, 90 days to 1 year, and more than 1 year of the included studies were 0.21 (95% CI 0.18 to 0.24), 0.29 (95% CI 0.25 to 0.34) and 0.38 (95% CI 0.32 to 0.45), respectively (online supplemental figure S2).
Table 1. Summary of eligible studies.
| Characteristics | Included studies (n=42) |
|---|---|
| Region | |
| America | 8 (19.0) |
| Asia | 8 (19.0) |
| Europe | 17 (40.5) |
| Others | 9 (21.4) |
| Study design | |
| Retrospective | 38 (90.5) |
| Prospective | 4 (9.5) |
| Case-control | 4 (9.5) |
| Cohort | 38 (90.5) |
| Sample size | 112.5 (18–656) |
| Definition of acute severe ulcerative colitis | |
| Truelove and Witts criteria | 30 (71.4) |
| Other criteria | 12 (28.6) |
| Follow-up period | |
| ≤12 months | 14 (33.3) |
| >12 months | 28 (66.7) |
| Concomitant medications | |
| Corticosteroids | 38 (90.5) |
| Infliximab | 26 (61.9) |
| Ciclosporin | 23 (54.8) |
| Others | 15 (35.7) |
Data were presented as counts N (percentage) or median (range).
Study quality assessment
Online supplemental table S4 shows the results of the quality assessment using the Newcastle-Ottawa Scale for each study. All included studies had a total score between six and nine, with one and 41 studies study rated as moderate38 and high quality, respectively.
Predictors for colectomy available for meta-analysis
Predictors for colectomy within 1 year
In 29 studies, multiple candidate predictors for colectomy within 1 year among patients with ASUC were identified, including biomarkers, past or current drug factors, demographic and clinical characteristics, and other auxiliary examination results.
Figure 1A illustrates the overall predictive power of biomarkers, including albumin, CRP, ESR and haemoglobin, for the risk of colectomy within 1 year. Four studies14 18 23 39 reported albumin level as a notable predictor for colectomy within 1 year, with each 1 g/dL increase in albumin level decreasing the probability of colectomy by approximately 61% (pooled OR (95% CI): 0.39 (0.26 to 0.59), I2=0.0%, p=0.454). Moreover, when compared with a high albumin level, the pooled OR of a low albumin level (<30 g/L) in five studies1115,17 21 was 2.34 (95% CI 1.61 to 3.39, I2=0.0%, p=0.931). High levels of CRP (≥25 mg/L) have been reported in five studies.15,1721 40 An overall OR of 2.63 (95% CI 1.53 to 4.52, I2=29.6%, p=0.224) suggested that it was an important risk factor for colectomy within 1 year. Four studies34,37 demonstrated the predictive value of the Oxford criteria, which were defined as CRP levels exceeding 45 mg/L in conjunction with 3–8 bowel movements in 24 hours, or independently, more than 8 bowel movements per day on days 3 of intravenous corticosteroids. Compared with patients failing to satisfy the Oxford criteria, those who met the Oxford criteria exhibited a statistically significant elevation in risk of colectomy, with an overall OR of 4.42 (95% CI 2.85 to 6.84, I²=0.0%, p=0.701). However, no significant predictive effect of CRP as a continuous variable was found despite heterogeneity13 14 18 39 (OR (95% CI): 1.00 (0.98 to 1.02), I2=60.4%, p=0.056). Similarly, patients with high levels of ESR (>30 mm/hour) were shown to have a nearly three times higher risk of colectomy than patients with low ESR levels, with a pooled OR of 2.92 (95% CI 1.39 to 6.14, I2=0.0%, p=0.792) from two studies.17 21 Four other studies11 16 17 21 have reported on the performance of low haemoglobin levels (≤12 g/dL) in predicting colectomy in 1 year. Although some heterogeneity was observed among studies (I2=56.4%, p=0.076), the result indicated that a low haemoglobin level tended to increase the risk of colectomy within 1 year (OR (95% CI): 2.08 (1.07 to 4.07)).
Figure 1. Meta-analysis on predictors for colectomy within 1 year. (A) Biomarkers. (B) Drug factors. (C) Demographic and clinical characteristics. (D) Auxiliary examination results.
Prior corticosteroid exposure was found to significantly influence the risk of colectomy within 1 year, with a pooled OR from six studies15 17 20 22 39 40 of 1.75 (95% CI 1.23 to 2.50, I2=17.7%, p=0.299) (figure 1B). Similarly, patients with previous azathioprine use were more than twice as likely to undergo colectomy than those without prior exposure (figure 1B). The pooled OR of two studies33 39 was 2.25 (95% CI 1.28 to 3.96, I2=0.0%, p=0.927). Prior immunomodulator use,20 21 baseline aminosalicylate use,12 17 39 baseline immunomodulator use12 13 17 and high-dose IFX induction (10 mg/kg)12 14 19 44 were not significantly associated with future colectomy, although heterogeneity existed among studies of the former two factors (both I2>50%) (figure 1B).
No demographic factors exhibited predictive value for colectomy within 1 year, including age, newly diagnosed UC, sex, body mass index, disease duration and smoking status (figure 1C). However, there was considerable heterogeneity between studies on age, both as a continuous (I2=83.4%, p=0.000)12 13 18 42 and dichotomous variable (I2=86.5%, p=0.000).15 21 41 45 Besides, some heterogeneity observed among the three studies16 17 44 on newly diagnosed UC (I2=64.4%, p=0.060), 11 studies1112 15,18 20 21 33 39 44 on sex (I2=48.7%, p=0.041), and two studies12 21 on disease duration (I2=57.0%, p=0.127).
Disease extent was the most frequently investigated variable among the auxiliary examination findings, as reported in nine prognostic studies of ASUC.1115,18 20 23 33 39 Compared with patients with localised colitis, those with extensive colitis were more likely to undergo colectomy within 1 year, with an overall OR of 1.85 (95% CI 1.24 to 2.78, I2=47.5%, p=0.055) (figure 1D). Similarly, sarcopenia, a decrease in skeletal muscle mass and strength measured using CT at the third lumbar vertebra level, was a notable predictor of colectomy within 1 year. The pooled OR of two studies11 18 was 1.90 (95% CI 1.04 to 3.45, I2=0.0%, p=0.750) (figure 1D). No significant association was found between cytomegalovirus infection status and the occurrence of colectomy, as well as between Mayo endoscopic subscore and colectomy (figure 1D).
Predictors for colectomy within 90 days
Eighteen variables in 18 studies1114 17,23 33 34 36 37 39 were included in the meta-analyses for colectomy within 90 days. Among them, each 1 g/dL increase in albumin level and baseline use of aminosalicylate reduced the risk of patients undergoing colectomy within 90 days, with pooled OR values of 0.37 (95% CI 0.24 to 0.57, I2=0.0%, p=0.709) and 0.45 (95% CI 0.27 to 0.75, I2=0.0%, p=0.476), respectively (figure 2A). Five variables were identified as risk factors for colectomy within 90 days, including fulfilling the Oxford criteria (OR (95% CI): 4.69 (2.99 to 7.34), I2=0.0%, p=0.950), high ESR levels (OR (95% CI): 2.92 (1.39 to 6.14), I2=0.0%, p=0.792), previous corticosteroids exposure (OR (95% CI): 1.91 (1.19 to 3.07), I2=37.4%, p=0.172), previous azathioprine use (OR (95% CI): 2.25 (1.28 to 3.96), I2=0.0%, p=0.927) and sarcopenia (OR (95% CI): 2.60 (1.23 to 5.49), I2=0.0%, p=0.476) (figure 2A). Furthermore, the pooled results indicated that current smokers and cytomegalovirus infection were not significantly associated with the occurrence of colectomy within 90 days. The remaining variables did not demonstrate a predictive effect on colectomy, though significant heterogeneity among the studies was observed (figure 2B).
Figure 2. Meta-analysis on predictors with predictive value for colectomy within 90 days. (A) Variables with predictive values. (B) Variables without predictive values.
Predictors for colectomy during a follow-up period of more than 1 year
Six variables—UC endoscopic index of severity (UCEIS), disease extent, sex, stool frequency, age as a continuous variable and age >35 years—were proposed in several different studies to explore whether they could predict the occurrence of colectomy during a follow-up period longer than 1 year. Among them, UCEIS was the only proven satisfactory risk factor for colectomy, with a pooled OR of three studies26 27 32 of 2.41 (95% CI 1.72 to 3.39, I2=1.5%, p=0.362) (figure 3). Disease extent and sex, with seven2425 29,33 and nine2425 27,29 31 studies, respectively, showed no significant effect on the probability of long-term colectomy, although certain heterogeneity was observed among the studies.
Figure 3. Meta-analysis on predictors for colectomy during a follow-up period of more than 1 year.
Sensitivity analyses
Among the variables for colectomy within 1 year, 13 variables were reported in studies with different diagnostic criteria, of which 10 variables had a sufficient number of studies defining ASUC using the Truelove and Witts criteria. These were ultimately included in the sensitivity analysis to test the consistency of the results.11,1517 20 Similar associations were found between 1-year colectomy and all variables, except for albumin level and low haemoglobin level, which failed to maintain the statistically significant pooled results in sensitivity analysis despite the presence of heterogeneity (online supplemental figure S3).
Predictors for colectomy not available for meta-analysis
We systematically summarised the variables for the prediction of colectomy (regardless of positive or negative results) that did not qualify for the meta-analysis (online supplemental table S5). A total of 70 candidate predictors for colectomy within 1 year in patients with ASUC were discussed in 26 studies,11,1720 21 23 24 26 33 35 while 52 predictors for colectomy during a longer follow-up period were discussed in 12 studies.2425 27,29 31 32 38 43 50 In addition to biomarkers studied in the meta-analysis, faecal calprotectin was another promising predictor of colectomy within 1 year, demonstrating good predictive capacity across multiple studies. Different auxiliary examination findings, such as endoscopic factors, radiological findings and the detection of Clostridium difficile infection, have also been discussed in various studies. Additionally, the predictive power of several indexes used to predict intravenous steroid failure, such as the Ho index, Lindgren score, and Travis index, for colectomy has also been raised. However, while research on concomitant medication on admission was relatively abundant, there was limited research on the prediction of colectomy by previous drug exposure. The only two studies on prior biological exposure presented contradictory results, with previous use of anti-tumour necrosis factor (TNF) agents reported as a protective factor for colectomy, while prior use of IFX was deemed to have no impact on colectomy within 1 year.
Discussion
Predicting the risk of colectomy in patients with ASUC, so as to implement more aggressive treatment decisions and refined care for high-risk individuals, is integral to avoiding emergency surgery and is crucial for ASUC management. In this study, we systematically reviewed 42 articles on the potential predictors of colectomy in patients with ASUC and summarised the predictive effects of multiple variables through meta-analysis and descriptive synthesis. To the best of our knowledge, this is the first systematic review and meta-analysis focusing on the risk factors for colectomy in patients with ASUC. The variables identified with definite predictive values in this study can not only be used in the clinical context as independent predictors of colectomy but are also thought to be more significant for inclusion in the development of future predictive models.
In the current study, 10 variables were identified as effective predictors of colectomy within 1 year through meta-analysis. Increased CRP level, ESR level, bowel movement frequency and disease extent, indicating a higher degree of inflammation, were identified as risk factors for colectomy, along with the previous use of steroids or azathioprine. Conversely, improvements in nutritional and health status indicators, such as albumin level, haemoglobin level and skeletal muscle mass and strength, may contribute to lower odds of surgery. Fulfilling the Oxford criteria was identified as being associated with a higher risk of colectomy within 1 year, serving as the most effective tool currently available for predicting this outcome. Similar findings were established in predictors for 90-day colectomy. In addition, an increase in the UCEIS score was the only factor found to increase the likelihood of undergoing colectomy more than a year later. A recently published systematic review predicting outcomes in patients with ASUC stated that the majority of scoring systems for predicting response to intravenous corticosteroids, as well as short-term and long-term colectomy, incorporated clinical or laboratory parameters, and endoscopic assessment using UCEIS was also applied for outcome prediction.53 Variables selected in these scores, including albumin, CRP, stool frequency, UCEIS and previous anti-TNF or thiopurines, overlapped with the predictors found in our study. Another study by Adams et al developed and validated a prediction model composed of CRP, albumin and UCEIS to predict steroid non-response in patients with ASUC.54 While the clinical focus may differ, these findings underscore the universality of these factors across various clinical contexts of ASUC and further support their association with colectomies. Additionally, our study identified some predictors with predictive values that are less commonly considered in current scoring systems, such as haemoglobin levels, disease extent and concurrent sarcopenia, which will be a driving force for developing and refining prediction models specific to the outcome of colectomy. Furthermore, the results revealed that for certain predictors such as CRP level, a categorical form may be more significant in predicting the outcome of colectomy than a continuous form, suggesting that the monotonic or linear associations between these predictors and the outcome may require further scrutiny, and greater emphasis should be placed on the determination of optimal cut-off values in future prognostic studies.
Fifteen, ten and five variables were found to be unrelated to colectomy within 1 year, within 90 days and over a longer period, respectively. Notably, the predictive effects of 17 of these variables were significantly heterogeneous across the included studies. Restricted by the limited number of studies, we did not further explore the specific origins of this interstudy heterogeneity. However, this remained understandable because our eligibility criteria did not impose strict specifications on study types and designs, sources of patient data, baseline clinical settings, interventions during follow-up or specific timing of outcome occurrence. Therefore, we had limited confidence in guaranteeing that these variables could not predict the risk of colectomy in patients with ASUC. Further research on the predictive capacity of these variables for colectomy should be conducted, preferably on a large scale, with a prospective design in a specific clinical setting, and with satisfactory generalisability.
In our systematic review, numerous variables were not included in the quantitative synthesis due to an insufficient number of studies or the absence of ORs for analysis, and they were comprehensively summarised in tabular form, which resulted in our inability to derive an overall effect of these variables in predicting colectomy. For instance, the only two studies discussing prior exposure to IFX and anti-TNF agents have yielded conflicting results, meaning that current evidence remains inadequate to definitively ascertain their effects on colectomy, though the meta-analysis showed that prior azathioprine exposure was a risk factor for colectomy. These controversial results may be related to whether the previous medication was administered as monotherapy or combination therapy. Due to the lack of additional studies to distinguish and compare these approaches, we are unable to draw specific conclusions. However, the qualitative results could still provide valuable information for clinicians and researchers, as all potential factors investigated in the existing studies were clearly presented. A notable topic for subsequent investigations is to validate the predictive power of these variables further to gain greater insight into their validity and robustness in predicting outcomes related to colectomies. In the meantime, additionally exploring the potential of other variable types to predict the outcome of colectomy is also of great importance. For instance, incorporating radiological findings may improve the accuracy of prediction of colectomy; however, current evidence is relatively insufficient. The potential value of omics data, such as genomics and metabolomics, for ASUC prognosis has also been previously proposed,55 but further progress is still needed. In addition, the diversity of reported results in the available studies highlights the need to follow uniform reporting guidelines in prognostic studies, which is essential for improving transparency, reproducibility and the comparison and synthesis of evidence.
IFX, ciclosporin and tacrolimus have been recognised as salvage therapeutic options for patients with steroid-refractory ASUC, acting as alternatives to surgical intervention.56 However, not all patients could respond to salvage therapy and maintain colectomy-free survival.57 58 In cases where salvage therapy with a particular drug fails, the adoption of sequential therapy with another agent is controversial, as secondary treatment failure may result in delaying surgery, potentially increasing mortality or the risk of postoperative complications.59 Furthermore, existing evidence showed that even if the treatment is effective, a significant proportion of patients would experience relapse or even require colectomy during follow-up.57 59 Thus, early prediction of the probability of colectomy and risk stratification of patients could aid in timely surgical decision-making for high-risk patients, allowing adequate preparation for colectomy at the most appropriate time. This study contributes to the existing literature on this topic. The remaining challenges include the lack of prospective assessments of the optimal timing of surgery, the controversy of the advantages and disadvantages of sequential therapy and the benefits of personalised dosing strategies, such as prolonging administration periods, increasing dosages and accelerating dosing.1 60 Therefore, further normative studies are needed to address these issues.
This study has some limitations. First, colectomy among patients did not occur at a specific time node but occurred within a prespecified time range in our study, which may have contributed to some variability. However, our results showed that for most predictors, there was no significant heterogeneity among the studies in the calculation of the overall effect sizes. Second, we used unadjusted OR as the effect size for pooling without considering the influence of potential confounding factors, which may have affected the results. Variations in populations, study designs and outcomes across studies could have led to OR value without adjustment for confounders that are more likely to deviate from the true value, which could have contributed to the observed heterogeneity. Third, the number of articles that could be used for the meta-analysis was relatively limited for some predictors, which may have affected the persuasiveness and robustness of our results. Furthermore, the lack of information in the original texts to calculate the pooled OR values prevented some studies from being included in the meta-analysis, which may have introduced bias. Therefore, we conducted a tabulation summary of other parameters reflecting the predictive power of these factors as a supplement to the meta-analysis, hoping that it could provide some reference for clinical practice or future research.
In conclusion, this systematic review and meta-analysis of the predictors of colectomy in patients with ASUC identified several significant factors such as albumin, CRP, ESR, haemoglobin, Oxford criteria, UCEIS, disease extent, previous use of steroids or azathioprine and concurrent sarcopenia, as predictors for colectomy risk. In future studies and clinical practice, a comprehensive consideration of different factors, including biomarkers, endoscopic and CT findings, demographic and clinical characteristics, and drug factors, will facilitate risk stratification and personalised treatment, thereby reducing the occurrence of colectomy and improving patient prognosis.
Supplementary material
Footnotes
Funding: This work was supported by the National Natural Science Foundation of China (#82270555, #82070538) and the China Crohn’s & Colitis Foundation (CCCF) under Grant no. CCCF-QF-2022B36-7.
Provenance and peer review: Not commissioned; externally peer reviewed.
Patient consent for publication: Not applicable.
Ethics approval: Not applicable.
Data availability free text: The datasets generated for this study are available on request from the corresponding authors.
Data availability statement
Data are available upon reasonable request.
References
- 1.Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:482–513. doi: 10.1111/apt.13491. [DOI] [PubMed] [Google Scholar]
- 2.Lynch RW, Lowe D, Protheroe A, et al. Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther. 2013;38:935–45. doi: 10.1111/apt.12473. [DOI] [PubMed] [Google Scholar]
- 3.Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohn's Colitis. 2010;4:431–7. doi: 10.1016/j.crohns.2010.02.001. [DOI] [PubMed] [Google Scholar]
- 4.Dong C, Metzger M, Holsbø E, et al. Systematic review with meta‐analysis: mortality in acute severe ulcerative colitis. Aliment Pharmacol Ther . 2020;51:8–33. doi: 10.1111/apt.15592. [DOI] [PubMed] [Google Scholar]
- 5.Chen J ‐H., Andrews JM, Kariyawasam V, et al. Review article: acute severe ulcerative colitis – evidence‐based consensus statements. Aliment Pharmacol Ther . 2016;44:127–44. doi: 10.1111/apt.13670. [DOI] [PubMed] [Google Scholar]
- 6.Hindryckx P, Jairath V, D’Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol . 2016;13:654–64. doi: 10.1038/nrgastro.2016.116. [DOI] [PubMed] [Google Scholar]
- 7.Gupta V, Mohsen W, Chapman TP, et al. Predicting Outcome in Acute Severe Colitis-Controversies in Clinical Practice in 2021. J Crohns Colitis. 2021;15:1211–21.:jjaa265. doi: 10.1093/ecco-jcc/jjaa265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:71.:n71. doi: 10.1136/bmj.n71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954;2:375–8. doi: 10.1136/bmj.2.4884.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. doi: 10.1136/bmj.327.7414.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ge X, Xia J, Wu Y, et al. Sarcopenia assessed by computed tomography is associated with colectomy in patients with acute severe ulcerative colitis. Eur J Clin Nutr. 2022;76:410–8. doi: 10.1038/s41430-021-00953-y. [DOI] [PubMed] [Google Scholar]
- 12.Con D, Andrew B, Nicolaides S, et al. Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy. Intest Res. 2022;20:101–13. doi: 10.5217/ir.2020.00146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Battat R, Hemperly A, Truong S, et al. Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021;19:511–8. doi: 10.1016/j.cgh.2020.03.072. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Syal G, Robbins L, Kashani A, et al. Hypoalbuminemia and Bandemia Predict Failure of Infliximab Rescue Therapy in Acute Severe Ulcerative Colitis. Dig Dis Sci. 2021;66:199–205. doi: 10.1007/s10620-020-06177-7. [DOI] [PubMed] [Google Scholar]
- 15.Le Baut G, Kirchgesner J, Amiot A, et al. A Scoring System to Determine Patients’ Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021;19:1602–10. doi: 10.1016/j.cgh.2019.12.036. [DOI] [PubMed] [Google Scholar]
- 16.Wu H, Wei J, Li J, et al. Serum Procalcitonin as a Potential Early Predictor of Short-Term Outcomes in Acute Severe Ulcerative Colitis. Dig Dis Sci. 2019;64:3263–73. doi: 10.1007/s10620-018-5446-0. [DOI] [PubMed] [Google Scholar]
- 17.Patrick D, Doecke J, Irwin J, et al. The effect of pre-admission immunosuppression on colectomy rates in acute severe ulcerative colitis. Therap Adv Gastroenterol. 2018;11:1756284818809789. doi: 10.1177/1756284818809789. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Cushing KC, Kordbacheh H, Gee MS, et al. Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients. J Crohns Colitis. 2018;12:1036–41. doi: 10.1093/ecco-jcc/jjy064. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Shah SC, Naymagon S, Panchal HJ, et al. Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis. Inflamm Bowel Dis. 2018;24:651–9. doi: 10.1093/ibd/izx039. [DOI] [PubMed] [Google Scholar]
- 20.Jain S, Kedia S, Sethi T, et al. Predictors of long‐term outcomes in patients with acute severe colitis: A northern Indian cohort study. J of Gastro and Hepatol. 2018;33:615–22. doi: 10.1111/jgh.13921. [DOI] [PubMed] [Google Scholar]
- 21.Deiana S, Bagnoli S, Manetti N, et al. Outcome of acute severe ulcerative colitis in patients previously exposed to immunosuppressive therapy. Dig Liver Dis. 2016;48:1432–7. doi: 10.1016/j.dld.2016.07.021. [DOI] [PubMed] [Google Scholar]
- 22.Barnes A, Spizzo P, Mountifield R. Corticosteroid exposure prior to admission and predicting need for rescue therapy in acute severe ulcerative colitis. Intern Med J. 2022;52:828–33. doi: 10.1111/imj.15131. [DOI] [PubMed] [Google Scholar]
- 23.Lian L, Fazio VW, Hammel J, et al. Impact of narcotic use on the requirement for colectomy in inpatients with ulcerative colitis. Dis Colon Rectum. 2010;53:1295–300. doi: 10.1007/DCR.0b013e3181e7562c. [DOI] [PubMed] [Google Scholar]
- 24.Beswick L, Rosella O, Rosella G, et al. Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study. J Crohn's Colitis. 2018;12:289–97. doi: 10.1093/ecco-jcc/jjx146. [DOI] [PubMed] [Google Scholar]
- 25.Al-Darmaki A, Hubbard J, Seow CH, et al. Clinical Predictors of the Risk of Early Colectomy in Ulcerative Colitis: A Population-based Study. Inflamm Bowel Dis. 2017;23:1272–7. doi: 10.1097/MIB.0000000000001211. [DOI] [PubMed] [Google Scholar]
- 26.Fernandes SR, Santos P, Miguel Moura C, et al. The use of a segmental endoscopic score may improve the prediction of clinical outcome in acute severe ulcerative colitis. Rev Esp Enferm Dig . 2016;108:697–702. doi: 10.17235/reed.2016.4470/2016. [DOI] [PubMed] [Google Scholar]
- 27.Corte C, Fernandopulle N, Catuneanu AM, et al. Association Between the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Outcomes in Acute Severe Ulcerative Colitis. J Crohn's Colitis. 2015;9:376–81. doi: 10.1093/ecco-jcc/jjv047. [DOI] [PubMed] [Google Scholar]
- 28.Pagoldh M, Lange S, Jennische E, et al. Faecal analysis and plasma complement factor 3c levels at admission for an acute attack of ulcerative colitis are predictive of the need for colectomy. Eur J Gastroenterol Hepatol. 2014;26:295–300. doi: 10.1097/MEG.0000000000000042. [DOI] [PubMed] [Google Scholar]
- 29.Molnár T, Farkas K, Nyári T, et al. Response to first intravenous steroid therapy determines the subsequent risk of colectomy in ulcerative colitis patients. J Gastrointestin Liver Dis . 2011;20:359–63. [PubMed] [Google Scholar]
- 30.Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905–10. doi: 10.1136/gut.38.6.905. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Chew CN, Nolan DJ, Jewell DP. Small bowel gas in severe ulcerative colitis. Gut. 1991;32:1535–7. doi: 10.1136/gut.32.12.1535. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Xie T, Zhang T, Ding C, et al. Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Score (MES) in guiding the need for colectomy in patients with acute severe colitis. Gastroenterol Rep (Oxf) 2018;6:38–44. doi: 10.1093/gastro/gox016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Moskovitz DN, Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760–5. doi: 10.1016/j.cgh.2006.04.001. [DOI] [PubMed] [Google Scholar]
- 34.Moore AC, Bressler B. Acute Severe Ulcerative Colitis: The Oxford Criteria No Longer Predict In-Hospital Colectomy Rates. Dig Dis Sci. 2020;65:576–80. doi: 10.1007/s10620-019-05668-6. [DOI] [PubMed] [Google Scholar]
- 35.Bernardo S, Fernandes SR, Gonçalves AR, et al. Predicting the Course of Disease in Hospitalized Patients With Acute Severe Ulcerative Colitis. Inflamm Bowel Dis. 2019;25:541–6. doi: 10.1093/ibd/izy256. [DOI] [PubMed] [Google Scholar]
- 36.Lee H-S, Park SH, Kim S-H, et al. Risk Factors and Clinical Outcomes Associated with Cytomegalovirus Colitis in Patients with Acute Severe Ulcerative Colitis. Inflamm Bowel Dis. 2016;22:912–8. doi: 10.1097/MIB.0000000000000675. [DOI] [PubMed] [Google Scholar]
- 37.Lynch RW, Churchhouse AMD, Protheroe A, et al. Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using UK IBD audit data. Aliment Pharmacol Ther . 2016;43:1132–41. doi: 10.1111/apt.13614. [DOI] [PubMed] [Google Scholar]
- 38.Allison J, Herrinton LJ, Liu L, et al. Natural history of severe ulcerative colitis in a community-based health plan. Clin Gastroenterol Hepatol . 2008;6:999–1003. doi: 10.1016/j.cgh.2008.05.022. [DOI] [PubMed] [Google Scholar]
- 39.Ho GT, Mowat C, Goddard CJR, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second‐line medical therapy or surgery. Aliment Pharmacol Ther . 2004;19:1079–87. doi: 10.1111/j.1365-2036.2004.01945.x. [DOI] [PubMed] [Google Scholar]
- 40.Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol. 1998;10:831–6. doi: 10.1097/00042737-199810000-00003. [DOI] [PubMed] [Google Scholar]
- 41.Boyd T, Araka EB, Kochar B, et al. Differences in Management and Outcomes of Older and Younger Adults with Acute Severe Ulcerative Colitis. J Crohn's Colitis. 2024;18:570–7. doi: 10.1093/ecco-jcc/jjad183. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.García MJ, Riestra S, Amiot A, et al. Effectiveness and safety of a third‐line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study) Aliment Pharmacol Ther . 2024;59:1248–59. doi: 10.1111/apt.17938. [DOI] [PubMed] [Google Scholar]
- 43.Huang D, Rennie M, Krasovec A, et al. Impact of cytomegalovirus on outcomes in acute severe ulcerative colitis: a retrospective observational study. Ther Adv Chronic Dis. 2024;15:20406223241233203. doi: 10.1177/20406223241233203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Clark N, MacIsaac M, Little R, et al. Have changing practices in salvage medical options affected colectomy rates in acute severe ulcerative colitis? Intern Med J. 2023;53:2231–9. doi: 10.1111/imj.16074. [DOI] [PubMed] [Google Scholar]
- 45.Subhaharan D, Ramaswamy PK, Willmann L, et al. Older adults with acute severe ulcerative colitis have similar steroid non-response and colectomy rates as younger adults. World J Gastroenterol. 2023;29:2469–78. doi: 10.3748/wjg.v29.i16.2469. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104:673–8. doi: 10.1038/ajg.2008.119. [DOI] [PubMed] [Google Scholar]
- 47.Ma R, Meng R, Zhang X, et al. Correlation between fecal calprotectin, ulcerative colitis endoscopic index of severity and clinical outcome in patients with acute severe colitis. Exp Ther Med. 2020;20:1498–504. doi: 10.3892/etm.2020.8861. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Ostrowski S, Croft A. Viral Enteric Infections in Acute Severe Ulcerative Colitis. J Crohn's Colitis. 2022;16:1335–9. doi: 10.1093/ecco-jcc/jjac028. [DOI] [PubMed] [Google Scholar]
- 49.Gibson DJ, Heetun ZS, Redmond CE, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:330–5. doi: 10.1016/j.cgh.2014.07.041. [DOI] [PubMed] [Google Scholar]
- 50.Kobayashi T, Naganuma M, Okamoto S, et al. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. J Gastroenterol. 2010;45:1129–37. doi: 10.1007/s00535-010-0273-x. [DOI] [PubMed] [Google Scholar]
- 51.Zhang M, Lv H, Yang H, et al. Elderly Patients with Moderate-To-Severe Ulcerative Colitis Are More Likely to Have Treatment Failure and Adverse Outcome. Gerontology. 2023;69:119–29. doi: 10.1159/000522569. [DOI] [PubMed] [Google Scholar]
- 52.Monterubbianesi R, Aratari A, Armuzzi A, et al. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. J Crohn's Colitis. 2014;8:852–8. doi: 10.1016/j.crohns.2014.01.006. [DOI] [PubMed] [Google Scholar]
- 53.Kayal M, Meringer H, Martin L, et al. Systematic review: Scores used to predict outcomes in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2023;58:974–83. doi: 10.1111/apt.17731. [DOI] [PubMed] [Google Scholar]
- 54.Adams A, Gupta V, Mohsen W, et al. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response. Gut. 2023;72:433–42. doi: 10.1136/gutjnl-2022-327533. [DOI] [PubMed] [Google Scholar]
- 55.Travis S, Satsangi J, Lemann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut. 2011;60:3–9. doi: 10.1136/gut.2010.216895. [DOI] [PubMed] [Google Scholar]
- 56.Nakase H. Acute Severe Ulcerative Colitis: Optimal Strategies for Drug Therapy. Gut Liver. 2023;17:49–57. doi: 10.5009/gnl220017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut. 2018;67:237–43. doi: 10.1136/gutjnl-2016-313060. [DOI] [PubMed] [Google Scholar]
- 58.Komaki Y, Komaki F, Ido A, et al. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. ECCOJC . 2016;10:484–94. doi: 10.1093/ecco-jcc/jjv221. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Harbord M, Eliakim R, Bettenworth D, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017;11:769–84. doi: 10.1093/ecco-jcc/jjx009. [DOI] [PubMed] [Google Scholar]
- 60.Narula N, Fine M, Colombel JF, et al. Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks. Inflamm Bowel Dis. 2015;21:1683–94. doi: 10.1097/mib.0000000000000350. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Data are available upon reasonable request.



